Código QR (código de barras bidimensional)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4. Considering the therapeutic indications, tegopra...

תיאור מלא

שמור ב:
Principais autores: Lien Thi Ngo, Jaeyeon Lee, Hwi-yeol Yun, Jung-woo Chae
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI AG 2023-01-01
סדרה:Pharmaceutics
נושאים:
tegoprazan
PBPK model
drug–drug interaction
CYP3A4
metabolism
גישה מקוונת:https://www.mdpi.com/1999-4923/15/1/182
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים